Last reviewed · How we verify

Symbicort Turbuhaler — Competitive Intelligence Brief

Symbicort Turbuhaler (Symbicort Turbuhaler) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination. Area: Respiratory.

phase 3 Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Symbicort Turbuhaler (Symbicort Turbuhaler) — Orion Corporation, Orion Pharma. Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Symbicort Turbuhaler TARGET Symbicort Turbuhaler Orion Corporation, Orion Pharma phase 3 Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS Salmeterol 50 mcg via DISKUS GlaxoSmithKline marketed Long-acting beta2-adrenergic agonist (LABA) Beta2-adrenergic receptors
Symbicort® Turbohaler® Inhalation Powder Symbicort® Turbohaler® Inhalation Powder Pearl Therapeutics, Inc. phase 3 Inhaled corticosteroid/long-acting beta2-adrenergic agonist Beta2-adrenergic receptor
Seretide Evohaler Seretide Evohaler FLUIDDA nv phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Spiromax Budesonide/formoterol Spiromax Budesonide/formoterol University Medical Center Groningen phase 3 Corticosteroid/long-acting beta2-adrenergic receptor agonist Beta2-adrenergic receptor
Symbicort TBH - Turbuhaler Symbicort TBH - Turbuhaler AstraZeneca phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Salmeterol/Fluticasone propionate combination product Salmeterol/Fluticasone propionate combination product GlaxoSmithKline phase 3 Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination class)

  1. Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Symbicort Turbuhaler — Competitive Intelligence Brief. https://druglandscape.com/ci/symbicort-turbuhaler. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: